Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 1005

Drug Profile

AB 1005

Alternative Names: AAV2-GDNF; AAV2-GDNF-MSA; AAV2-GDNF-PD; AB-1005; Adeno-associated-virus-GDNF-therapy-Brain Neurotherapy Bio; AMT-140; GDNF gene therapy - Brain Neurotherapy Bio; Glial cell line derived neurotrophic factor gene therapy-Brain Neurotherapy Bio

Latest Information Update: 06 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Brain Neurotherapy Bio; Lund University; National Institute of Neurological Disorders and Stroke; uniQure; University of California at San Francisco
  • Class Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Parkinson's disease
  • Phase I Multiple system atrophy

Most Recent Events

  • 29 Feb 2024 Asklepios Biopharmaceutical and Bayer plans to initiate a phase I (REGENERATE-PD) trial for Parkinson Disease (intraputaminal, Infusion) in April 2024 (NCT06285643)
  • 17 Nov 2023 Asklepios Biopharmaceutical completes enrolment in phase Ib trial for Parkinson's disease in USA (Intracerebral) (NCT04167540)
  • 29 Mar 2023 Preliminary efficacy and adverse events data from a phase I trial in Parkinson's disease presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top